Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized amoxicillin-clavulanic acid sputum levels in hospitalized acute exacerbation of COPD
NL-OMON28084Not yet recruiting
- Sponsor
- Medisch Spectrum Twente
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amoxicillin + clavulanate in chronic obstructive pulmonary disease (COPD), sponsored by Medisch Spectrum Twente. Primary endpoint: Sputum amoxicillin concentration exposure. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
amoxicillin + clavulanate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON28084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28084.